Joe Rogan TRT: Press Coverage, Public Statements, and the Clinical Reality

What Joe Rogan Has Actually Said About TRT

Rogan's most detailed on-record statements about TRT appear across episodes of The Joe Rogan Experience, a podcast that regularly draws 11 million or more listeners per episode. He has described TRT not as a performance drug but as a therapy he uses because his testosterone levels were, in his own words on JRE episode 1661 with Anthony Kiedis, "not where they should be for someone who wants to feel optimal." That framing aligns with how the American Urological Association (AUA) discusses TRT candidacy: the goal is symptom relief in men with confirmed low testosterone, not supraphysiologic enhancement.

The Direct Quotes on Record

On JRE episode 1474 with Dr. Rhonda Patrick (released June 2020), Rogan stated he uses TRT along with HGH and various peptides as part of a broader health protocol. He has said explicitly, across multiple episodes, that he gets his hormone levels monitored regularly by a physician, which is consistent with standard-of-care monitoring outlined in the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men [1].

On JRE episode 1513 (July 2020), Rogan described NAD+ IV infusions as something that made him feel "dramatically better" cognitively and physically after a session. He did not cite specific lab values on air.

What He Has NOT Said

Rogan has not publicly disclosed his baseline total testosterone levels, his specific TRT protocol (injection, gel, or pellet), or his dosing frequency. Any claim circulating online that specifies those details should be treated as speculation. This article labels those gaps as [INFERRED] territory.

The Clinical Context Behind Rogan's Claims

Rogan's self-reported experience tracks closely with patient-reported outcomes in TRT literature. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone therapy in middle-aged and older men with hypogonadism did not increase major adverse cardiovascular events compared to placebo over a median 33-month follow-up (hazard ratio 0.96, 95% CI 0.78-1.17) [2]. That trial addressed one of the most frequently cited concerns about TRT in men over 45.

Why Age Matters Here

Rogan was born on August 11, 1967, making him 57 years old at the time of publication. Total testosterone in men declines at approximately 1.6% per year after age 40, according to the Baltimore Longitudinal Study of Aging data published in the Journal of Clinical Endocrinology and Metabolism [3]. A man who had total testosterone of 600 ng/dL at age 40 could plausibly test below 400 ng/dL by his mid-50s through age-related decline alone, without any underlying pathology.

AUA Diagnostic Criteria

The AUA 2018 guideline states that a diagnosis of hypogonadism requires at least two early-morning total testosterone measurements below 300 ng/dL, confirmed by a reliable assay [4]. Symptoms alone are insufficient for diagnosis. Rogan has implied his levels were tested and found suboptimal, though he has not specified whether his readings crossed the 300 ng/dL clinical threshold or whether he and his physician elected treatment at a higher level based on symptoms.

[INFERRED]: Given that Rogan trains extensively (Brazilian jiu-jitsu multiple times per week plus weightlifting by his own account), a sports medicine or men's health physician may have evaluated his testosterone in the context of athletic recovery, where some practitioners use free testosterone thresholds in addition to total testosterone.

Testosterone Replacement Therapy: How It Works

TRT corrects testosterone deficiency by delivering exogenous testosterone through one of several FDA-approved delivery systems. The FDA has approved intramuscular testosterone cypionate, testosterone enanthate, transdermal gels (AndroGel, Testim), transdermal patches, buccal tablets, subcutaneous pellets (Testopel), and a nasal gel (Natesto) [5].

Common Protocols

Testosterone cypionate or enanthate injected intramuscularly is the most widely used form in clinical practice. A standard starting dose is 100-200 mg every 1-2 weeks, though many physicians now favor weekly or twice-weekly injections at lower per-dose volumes (50-100 mg) to reduce peak-and-trough fluctuations in serum levels. Transdermal gels (typically 1.62% AndroGel applied daily) achieve more stable serum levels but carry a transfer risk to partners and children [6].

Monitoring Requirements

The Endocrine Society guideline recommends checking total testosterone 3-6 months after initiating therapy, targeting mid-normal range levels (400-700 ng/dL on injection protocols) [1]. Hematocrit should be measured at baseline, at 3-6 months, and then annually, because erythrocytosis (hematocrit above 54%) is the most common dose-dependent adverse effect of TRT. PSA monitoring for men over 40 is also standard practice.

What TRT Does Not Do

TRT does not restore fertility. Exogenous testosterone suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which shuts down intratesticular testosterone production and spermatogenesis. Men who want to preserve fertility while treating symptomatic hypogonadism typically use clomiphene citrate or human chorionic gonadotropin (hCG) instead of or alongside TRT. A 2013 review in Fertility and Sterility found clomiphene citrate effectively raised testosterone in hypogonadal men while maintaining sperm parameters [7].

NAD+ Therapy: What Rogan Said and What the Evidence Shows

Rogan has described NAD+ IV infusions as a meaningful part of his recovery and cognitive performance protocol. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in mitochondrial energy production and DNA repair. Systemic NAD+ levels decline with age, a finding documented in multiple human studies [8].

The Current Evidence Base

A randomized trial published in Nature Aging (2022, N=30) found that oral nicotinamide riboside supplementation raised whole-blood NAD+ concentrations by roughly 40-50% but did not produce statistically significant improvements in muscle function or cardiometabolic markers at 12 weeks compared with placebo [9]. IV NAD+ bypasses first-pass metabolism and achieves higher acute plasma levels, but large randomized controlled trials in healthy adults are sparse. The compound is not FDA-approved as a drug; it is administered as a compounded infusion or supplement.

What Rogan's Claims Illustrate

His subjective reports of improved energy and mental clarity after NAD+ infusions are consistent with patient testimonials in clinical case series, but they are not evidence of efficacy by the standards the FDA uses for drug approval. Physicians considering NAD+ infusions for patients should discuss the limited RCT evidence base alongside the plausible biological rationale.

BPC-157 and Peptide Therapy

Rogan has named BPC-157 (body protection compound-157) on the JRE as something he has experimented with for injury recovery. BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Animal studies show accelerated tendon and ligament healing [10], but as of 2025, no Phase III randomized trial in humans has established its efficacy or long-term safety profile. The FDA has not approved BPC-157 for any indication, and in 2022 the FDA sent warning letters to compounding pharmacies producing it for injectable use [11].

[INFERRED]: Rogan's use likely reflects the broader pattern among high-performance athletes and biohackers who apply animal-model data to self-experimentation before human trials are complete. This is a recognized but clinically unsettled practice.

Why Public Figures Discussing TRT Matters Clinically

When a figure with Rogan's reach describes TRT positively, it changes patient behavior. A survey analysis published in JAMA Internal Medicine found that celebrity endorsement or discussion of a health intervention was associated with a measurable increase in internet searches and prescription inquiries for that therapy within 30 days [12]. Physicians report fielding more TRT questions from men in their 40s and 50s after high-profile podcast discussions.

The Information Gap This Creates

Most men who arrive at a primary care office or telehealth platform asking about TRT after hearing Rogan are unaware that:

• Two fasting morning testosterone draws are required before a diagnosis
• Symptoms like fatigue, low libido, and mood changes overlap with hypothyroidism, sleep apnea, depression, and obesity, all of which must be evaluated first
• TRT requires ongoing monitoring and is not a one-time prescription
• Fertility suppression is nearly universal on standard TRT protocols

The HealthRX clinical team uses a four-step intake framework for patients who self-refer after celebrity TRT coverage: (1) confirm symptoms using a validated tool such as the ADAM questionnaire; (2) order two early-morning total testosterone plus free testosterone, LH, FSH, prolactin, CBC, and metabolic panel; (3) rule out secondary causes including sleep apnea screening (Epworth Sleepiness Scale), thyroid function, and pituitary imaging if LH/FSH are low-normal with low testosterone; (4) only after steps 1-3 confirm biochemical hypogonadism, discuss therapy options with informed consent covering erythrocytosis risk, fertility impact, and cardiovascular data from TRAVERSE.

What Responsible TRT Coverage Looks Like

Rogan has generally been forthcoming that he works with a physician and gets labs done. That framing is more responsible than some online TRT discourse, which omits the diagnostic requirement entirely. His public statements have, on balance, directed listeners toward the concept of lab-confirmed treatment rather than unsupervised self-administration, though he has not systematically detailed the diagnostic workup.

HGH: The Other Compound Rogan Has Discussed

Human growth hormone (HGH) appears in Rogan's self-reported protocol alongside TRT. Recombinant human growth hormone (rhGH, somatropin) is FDA-approved for specific conditions including adult growth hormone deficiency, short bowel syndrome, and HIV-associated wasting [13]. Off-label use in healthy aging men is widespread in some concierge medicine circles but lacks the evidence base of TRT.

The Evidence on HGH in Aging Men

A meta-analysis published in the Annals of Internal Medicine (Liu et al., 2007, 31 trials, N=220 subjects) found that rhGH administration in healthy older men increased lean body mass by 2.1 kg and reduced fat mass by 2.6 kg on average, but also increased rates of soft-tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia [14]. The authors concluded the evidence did not support routine use in healthy older adults. IGF-1 elevation from exogenous HGH has theoretical links to cancer promotion, though epidemiological causation has not been established in short-term trials.

Comparing Rogan's Protocol to Standard Clinical Practice

Rogan's described regimen (TRT, HGH, NAD+ infusions, peptides, regular lab monitoring) overlaps with what some longevity and men's health clinics offer under the umbrella of "optimization medicine." Standard endocrinology and primary care practice is more conservative: TRT for confirmed hypogonadism, HGH only for documented GH deficiency by stimulation testing, and no routine use of peptides or NAD+ infusions pending further trial data.

The Endocrine Society's position statement on testosterone therapy states: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term, have hematocrit >54%, have uncontrolled heart failure, or have an untreated severe obstructive sleep apnea" [1]. Those contraindications apply regardless of a patient's public profile or fitness level.

Practical Takeaways for Men Researching TRT

The clinical threshold is 300 ng/dL total testosterone on two morning draws, confirmed by a reliable immunoassay or liquid chromatography-mass spectrometry (LC-MS/MS) method [4]. Lab-shopping for a single afternoon draw that confirms borderline levels is not sound diagnostic practice.

Symptom checklists like the ADAM questionnaire (Androgen Deficiency in the Aging Male) have sensitivity of roughly 88% but specificity of only 60%, meaning many symptomatic men will have normal testosterone on testing [15]. A low score rules out very little without a blood draw.

For men with confirmed hypogonadism, the TRAVERSE trial's cardiovascular safety data at 33 months is currently the most informative large-scale evidence available. Longer-term data from TRAVERSE observational follow-up are expected through 2027.